ONCY

Business Context and Reporting Period

Company: Oncolytics Biotech Inc.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Fiscal Year Ended December 31, 2005 (Filed March 3, 2006)
Business Overview: Oncolytics is a development-stage biopharmaceutical company focused on the discovery and development of REOLYSIN^®, a potential cancer therapeutic targeting Ras-mediated cancers. The company has no operating revenues from product sales and relies on interest income and equity financing.

Key Financial Metrics (Year Ended Dec 31, 2005)

Material Changes vs. Prior Period

• Revenue: Increased by approximately 12% to $783,456, driven primarily by higher interest income ($783,456 in 2005 vs. $699,757 in 2004) due to larger cash reserves.
• Net Loss: Slight decrease in net loss compared to 2004, despite higher operating expenses, largely due to a significant reduction in non-cash stock-based compensation expense ($64,104 in 2005 vs. $2,668,570 in 2004).
• Research & Development (R&D): Increased to $9,308,977 from $7,107,998. This was driven by higher manufacturing costs ($4.7M vs. $3.9M) and clinical trial expenses ($1.9M vs. $0.8M) as the company expanded trials in the U.S. and U.K.
• Liquidity: Total liquid assets increased to $40.4 million, supported by a private placement in Q4 2005 raising net proceeds of $15.4 million and warrant exercises raising $3.4 million.
• Investments: The company sold remaining shares of BCY Life Sciences Inc. and previously sold Transition Therapeutics Inc. shares, resulting in minimal gains/losses on sales in 2005 compared to a significant loss in 2003.

Guidance, Outlook, and Risks

Management Commentary and Outlook

• 2006 Cash Burn: Management estimates monthly cash usage will increase to approximately $1.5 million in 2006, up from the 2005 average, due to expanded clinical trials and manufacturing.
• Clinical Progress: The company expects to conclude patient enrollment in existing U.K. and U.S. Phase I trials in 2006 and move into Phase II trials. Preliminary data from the U.K. systemic delivery trial showed REOLYSIN^® was well-tolerated with evidence of tumor necrosis.
• Capital Resources: Management believes current capital resources ($40.4 million) are adequate to fund operations into 2008. Future funding requirements will likely be met through equity issuances.

Risks and Contingencies

• Development Risk: REOLYSIN^® is in the development stage; there is no assurance it will prove safe or effective in humans or receive regulatory approval (FDA/EMA).
• Manufacturing Dependence: The company relies on a single toll manufacturer in the U.K. for REOLYSIN^® production. Disruption could delay clinical trials.
• Contingent Obligations: A milestone payment of $1.0 million is outstanding, payable within 90 days of regulatory approval for REOLYSIN^®. Additionally, royalty obligations of 11.75% on partnership payments or 2.35% on net sales may apply upon commercialization.
• Product Liability: The company currently does not carry product liability insurance, which could inhibit commercialization if claims arise.

Key Facts for Investor Verification

• Cash Runway: Verify if the $40.4 million in liquid assets is sufficient to cover the projected $1.5 million monthly burn rate through 2008 without further dilution.
• Clinical Trial Data: Monitor upcoming data releases from the U.K. systemic delivery trial and the U.S. Phase I/II glioma trial to assess safety and efficacy signals.
• Manufacturing Capacity: Confirm the status of cGMP production runs with Cobra Biomanufacturing Plc to ensure supply for expanded 2006 trials.
• Regulatory Milestones: Track the status of the $1.0 million contingent milestone payment trigger (regulatory approval) and any new NCI clinical trial solicitations.
• Equity Dilution: Review the impact of outstanding warrants (2,784,800) and options (3,634,550) on future share count and potential dilution from future financing.